DOCSLIB.ORG

Report from the Scientific Programme Committee 21St ECNP Congress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Report from the Scientific Programme Committee 21St ECNP Congress 2009 Jan. 15, ecnp matters NEWSLETTER NO. Report from the Scientific Klaus-Peter Lesch st Winner ECNP Award Programme Committee 21 ECNP Page 2 Congress, 30 August - 3 September New initiative 2008, Barcelona, Spain ECNP School of Neuropsychopharmacology Sven Ove Ögren, Sweden, chair Page 2 It is a great pleasure to give my impression as a number of European scientists and the chair of the Scientific Programme Committee intensive evaluations of the proposals per- (SPC) to the 21st ECNP Congress in formed by members of the SPC. I hope that Next ECNP Congress Barcelona. As in the last two years, the con- this creative interaction between ECNP and Istanbul 2009 gress attracted a large number of delegates individual scientists can be further developed Pages 1, 3 and 4 (close to 7400) who filled the lecture rooms to make the ECNP Congresses outstanding from morning to late afternoons throughout events. In addition, there are now well devel- the congress. I was delighted to notice that oped avenues by which ECNP members Interview the three plenary lectures attracted such a and the ECNP Scientific Advisory Panels Jacques Glowinski large audience. It was satisfying to see that (SAP) contribute to the final programme Since 2006, ECNP organises Targeted symposium recent scientific achievements Page 4 the number of people wishing to attend a by organising the brainstorming sessions Expert Meetings (TEMs) ) to promote the have been presented. The lectures in the particular symposium was overall very high. and proposing the ECNP Targeted Expert exchange of ideas between members of the clinical Breaking News symposium were In addition, the audience has been very Meeting symposia, respectively. ECNP Scientific Advisory Panels (SAP), of high level, but there is a need for more active. I was particularly impressed by the experts, and European scientists between translational approaches. 21st ECNP Congress lively discussions and strong involvement Barcelona has further reinforced the tradi- 5-15 years post-doc. Four meetings are held 30 august – 3 September 2008 of the delegates. The lay-out of the congress tion within ECNP of blending innovative just before the ECNP Congress and partici- Summing up, the ECNP Congress in venue allowed the participants to encounter science with novel clinical applications and pation is by invitation only. The TEMs have Barcelona was undoubtedly a great success TEM symposia each other frequently thereby creating addi- therapeutic inventions. This development become very successful and we are grateful measured by any criteria. I am convinced tional possibilities for interactions. is reflected in the number of new initiatives for the input from all the participants and that everyone attending the congress feels S.05: Cognitive impairment in taken by ECNP during the last few years. the additional work done by the coordina- that he or she has learned many new interest- affective disorders: a potential The major aim of the SPC is to create a ECNP has taken the initiative to inspire tors. One of the output requirements for the ing things which captivated one’s scientific treatment target? high quality scientific programme with a and motivate young scientists in high qual- TEMs is to submit a symposium proposal imagination. I think that the 21st ECNP balanced mix between basic/clinical science ity research by special symposia called the for the next ECNP Congress. In Barcelona Congress gave all of us the lasting feeling S.11: Preclinical and translational and applied clinical developments. Another Hot Topics symposia. Selected presenta- four symposia have been submitted by the that there is a great future for neuropsychop- research in improving clinical outcomes in anxiety disorders important aim is to report on new and excit- tions from the annual ECNP Workshop TEMs from 2007. I am looking forward to harmacology in Europe. ing discoveries in the field of neuropsychop- in Nice in the Hot Topics symposia gave the contribution of the TEMs 2008 for the S.16: Neurogenesis and stem cell harmacology. I think that the 21st ECNP a good impression of the high quality of 22nd ECNP Congress in Istanbul. Finally, I would like to express once more my Congress, in an excellent manner, managed young scientists within Europe. I think thanks to all contributors, and in particular S.19: Translational issues in dementia to fulfil both these aims. This achievement everybody visiting these symposia was Our knowledge of brain mechanisms of the ECNP-Office, who made the 21st ECNP depends to a large extent on the input from impressed by the quality and variety of the relevance for health and disease is rapidly Congress such an overall success. many sources, i.e. symposium proposals, from presentations. increasing. In the preclinical Breaking News 22nd ECNP Congress: Submission Highlights ECNP Workshop on of papers is open Neuropsychopharmacology for The Scientific Programme Committee invites delegates who intend to present a Young Scientists in Europe 2009 poster to submit the corresponding paper. Eduard Vieta, Spain chair ECNP Workshop Committee The paper will be reviewed for presentation and publication. A paper that is not pub- As the new chair of the ECNP Workshop sions and are required to present a poster at lished can still be accepted for presentation. Committee, it is my pleasure to write a few one of the two poster sessions. During these words on the upcoming workshop to be held poster sessions there will be ample time to The deadline for submission is 31 March from 5-8 March 2009 in Nice, France. interact with the senior scientists. 2009. This year we will have as a fourth topic An additional stimulant for the selected For instructions on preparation of papers ‘Addiction: towards new drug targets’. For participants to prepare a high level poster and further information please visit the this session, we are very honoured that is the possibility to be selected by the ECNP website www.ecnp.eu. George Koob and Barbara Mason from the Workshop Committee for a presentation at Department of Neuropharmacology at the the 22nd ECNP Congress, 12 - 16 September Scripps Research Institute, La Jolla, USA 2009, Istanbul, Turkey. I can assure you this have accepted the invitation to share their opportunity is quite a challenge for both the vast experience in the field with the young poster presenters and the scientific commit- scientists in Europe. tee involved! All 90-100 invited young scientists are expected For further details on the programme to be present throughout the entire workshop, you are invited to visit the ECNP website as they play an active role during the discus- www.ecnp.eu. Call for symposia proposals for the 23rd ECNP Congress, 28 August - 1 September 2010, Amsterdam, The Netherlands The Scientific Programme Committee (SPC) by the SPC please visit the ECNP website is inviting you to submit a symposium pro- www.ecnp.eu. posal for the 23rd ECNP Congress. The deadline for submission is 31 March For details on the requirements for the 2009. proposal and the selection criteria handled 1 Interview with the winner of the 2008 ECNP Neuropsychopharmacology Award in Clinical Research: Klaus-Peter Lesch, Germany How does it feel to be one of the authors small effects, and an important question is of what appeared to be a ‘key’ paper in how these small effects interact to lead to the research for personality traits that a phenotype. On the other hand, there is editor influence mental diseases and their treat- as yet no concept to answer the question ment? How did this influence you and whether genetic testing for genes involved your work? in a complex trait or behavioural disorders is predictive for moderating events across the The discovery of serotonin transporter gene entire lifespan such as developmental and variation and its role in personality dimen- adult neuroplasticity. Although the inter- sions itself was a small first step; however, it individual variability is huge and many dif- resulted in extensive follow-up research by ferent aspects are involved at a genetic level, our group and independent investigators on the ultimate goal is to find the molecular Maria Vrijmoed Maria – Vrijmoed de Vries The Netherlands, interview different perspectives such as anxiety, stress basis that regulates behaviour. Here, we tear effects and neuroimaging. It also opened down the myth about the uniqueness of new avenues of research, such as the impli- human behaviour but we also believe that cations for the ‘social brain’. There has been individuals are unique in a fundamental way. an educational update session on the societal This contrast makes the work for basic and implications of neuroscience chaired by me clinical scientists extremely difficult. at the 21st ECNP Congress in Barcelona. How do you look at the perceived lack of The work on serotonin transporter gene efficacy of antidepressants as reported in variation as a ‘model’ system in neurobi- the press? ology has been remarkably broad. Sixty years after the discovery of serotonin and I think this form of reporting by the 21st ECNP Congress 40 years of research on the binding site of press is primarily doing a disservice to the 30 August – 3 September 2008 serotonin reuptake inhibiting antidepres- patients by re-enforcing their confusion. sants, the focus is directed towards cloning Programme educational update The response of patients to antidepressants session E.06 genes and detecting gene variation as well is highly individual and also relates to the as understanding gene regulation. What personal relationship with the treating psy- Society and neuroscience: will be the next levels of complexity? In any chiatrist as well as other complementary the neuroethics conundrum case, we will require both basic and clinical components of therapy. Clinical trial situa- Moderator: Klaus-Peter Lesch, research approaches. We will have to proceed tions are often highly artificial and far away Germany toward an integration of molecular genetics from the therapeutic reality.
Load more

Recommended publications
  • Jacques Glowinski, Neurobiologist and Head of School
    Comptes Rendus Biologies Yves Agid Jacques Glowinski, neurobiologist and head of school Volume 343, issue 4 (2020), p. 11-14. Published: 21st April 2021 <https://doi.org/10.5802/crbiol.44> © Académie des sciences, Paris and the authors, 2020. Some rights reserved. This article is licensed under the Creative Commons Attribution 4.0 International License. http://creativecommons.org/licenses/by/4.0/ Les Comptes Rendus. Biologies sont membres du Centre Mersenne pour l’édition scientifique ouverte www.centre-mersenne.org Comptes Rendus Biologies 2020, 343, nO 4, p. 11-14 https://doi.org/10.5802/crbiol.44 Biographical Notes / Notices biographiques Jacques Glowinski, neurobiologist and head of school Jacques Glowinski, neurobiologiste et chef d’école Yves Agida a Institut du Cerveau et de la Moelle, GH Pitié-Salpêtrière, 47 Boulevard de l’Hôpital, 75013, Paris, France E-mail: [email protected] Manuscript received and accepted 16th February 2021. Scientists around the world, and especially mem- There are many great scientists. This was partic- bers of the Academy of Sciences, are reeling from ularly the case when neurobiology was being born the sudden, unexpected disappearance of Jacques in France in the 1970s. We cannot fail to mention Glowinski on November 4, 2020, at the age of 84. For the names of Jean-Pierre Changeux, Jean-Charles those who were close to him and all those who knew Schwartz, Michel Le Moal, and many others, who, at him, it was an immense sadness. the time, were the leaders of the discipline. So why ISSN (electronic) : 1768-3238 https://comptes-rendus.academie-sciences.fr/biologies/ 12 Yves Agid was Jacques Glowinski a scientist out of the ordinary? field.
    [Show full text]
  • Leslie Iversen University of Oxford
    OBITUARY - Julius Axelrod Julius Axelrod a Nobel-Prize winning scientist internationally known for his research on brain chemistry and pharmacology died on Wednesday December 29th at his home in Rockville, Maryland near the National Institute of Mental Health, where he worked for most of his career. He was 92. Dr Axelrod shared the 1970 Nobel Prize in Physiology or Medicine with Bernard Katz and Ulf von Euler for fundamental discoveries on neurotransmitters, the chemical messengers used as signals in the nervous system. When such chemicals are released from nerve cells they must be rapidly inactivated and it was widely assumed that this involved their degradation to other inert substances. But Axelrod discovered a completely novel mechanism for the inactivation of neurotransmitters, involving their recapture by the nerves from which they were released. He studied the catecholamine neurotransmitter noradrenaline, present in the peripheral sympathetic nervous system and in the brain. Experiments with radiolabelled noradrenaline showed that when it was injected into experimental animals some was metabolised as expected, but a substantial part of the injected material was taken up and retained unchanged in sympathetic nerves from which it could be released on nerve stimulation. Together with a visiting Austrian scientist, George Hertting, Axelrod in 1961 proposed that the inactivation of noradrenaline involved an uptake system that recaptured much of the neurotransmitter into the same nerves from which it was released. A French visitor, Jacques Glowinski, and Axelrod found that antidepressant drugs acted as powerful inhibitors of this uptake mechanism in brain – and thus acted to prolong the effects of the released neurotransmitter.
    [Show full text]
  • Importance of the Noradrenaline–Dopamine Coupling in the Locomotor Activating Effects of D-Amphetamine
    The Journal of Neuroscience, April 1, 1998, 18(7):2729–2739 Importance of the Noradrenaline–Dopamine Coupling in the Locomotor Activating Effects of D-Amphetamine Laurent Darracq, Ge´ rard Blanc, Jacques Glowinski, and Jean-Pol Tassin Institut National de la Sante´ et de la Recherche Me´ dicale U114, Colle` ge de France, 75231 Paris Cedex 05, France The locomotor hyperactivity induced by systemic or local (nu- DA levels in the nucleus accumbens, and this response was cleus accumbens) D-amphetamine injections can be blocked associated with simultaneous behavioral activation. Both the by systemic or local (prefrontal cortex) injections of prazosin, an increases in extracellular DA levels and in locomotor activity a1-adrenergic antagonist (Blanc et al., 1994). Microdialysis were completely blocked by a pretreatment with prazosin, in- studies performed on freely moving animals indicated that jected either systemically (0.5 mg/kg, i.p.) or locally and bilat- prazosin (0.5 mg/kg, i.p.) does not modify the increase in the erally into the prefrontal cortex (500 pmol/side). Complemen- extracellular dopamine (DA) levels in the nucleus accumbens tary experiments indicated that the focal application of that are induced by D-amphetamine (2.0 mg/kg, i.p.), but it D-amphetamine requires at least a 4.8-fold higher increase in inhibits the D-amphetamine-induced locomotor hyperactivity DA output compared with systemic D-amphetamine for the (263%, p , 0.0001). No behavioral activation occurred after behavioral effects to be elicited. Altogether, these results sug- the bilateral local perfusion of 3 mMD-amphetamine in the gest that locomotor activating effects of D-amphetamine are nucleus accumbens, although it led to a fivefold increase in caused by the stimulation of cortical a1-adrenergic receptors extracellular DA levels.
    [Show full text]
  • Sur Les Épaules Des Géants Qui Nous Ont Précédés Jacques Glowinski, De La Neuropharmacologie Biochimique À L’Architecture Hervé Chneiweiss REPÈRES
    Sur les épaules des géants qui nous ont précédés Hervé Chneiweiss To cite this version: Hervé Chneiweiss. Sur les épaules des géants qui nous ont précédés : Jacques Glowinski, de la neu- ropharmacologie biochimique à l’architecture. médecine/sciences, EDP Sciences, 2021, 37 (2), pp.185- 188. 10.1051/medsci/2021015. hal-03143638 HAL Id: hal-03143638 https://hal.archives-ouvertes.fr/hal-03143638 Submitted on 16 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. médecine/sciences 2021 ; 37 : 185-8 médecine/sciences Sur les épaules des géants qui nous ont précédés Jacques Glowinski, de la neuropharmacologie biochimique à l’architecture Hervé Chneiweiss REPÈRES Président du Comité d’éthique de l’Inserm, Directeur du laboratoire Neuroscience Paris Seine – IBPS, Équipe Plasticité gliale et tumeurs cérébrales, UMR8246 CNRS/ Comme il le disait lui-même en ouverture de chaque U1130 Inserm/Sorbonne Université, pot de thèse, célébration d’un article important, où Campus Pierre et Marie Curie, lors d’un départ, « ce n’est pas sans une certaine 7 quai Saint-Bernard, émotion » que j’écris ces lignes qui évoqueront trop 75005 Paris, France. brièvement la vie d’un maître que le COVID a emporté le [email protected] 4 novembre 2020.
    [Show full text]
  • Pierre J. Magistretti
    BK-SFN-NEUROSCIENCE_V11-200147-Magistretti.indd 178 15/06/20 8:31 AM Pierre J. Magistretti BORN: Milano, Italy September 30, 1952 EDUCATION: University of Geneva Medical School, Diploma (1977) University of Geneva Medical School, Doctorate (1979) University of California at San Diego, PhD (1982) APPOINTMENTS: Maître Assistant, Department of Pharmacology, University of Geneva (1982–1987) Professor, Department of Physiology, University of Lausanne Medical School (1988–2004) Chairman, Department of Physiology, University of Lausanne Medical School (2001–2004) Director, Brain Mind Institute, EPFL (2008–2012), Co-Director (2005–2008) Founding Director, Center for Psychiatric Neuroscience, University of Lausanne (2004–2012) Director, National Center for Competence SynaPsy (2010–2016) Distinguished Professor and Dean, KAUST (2012–) Professor Emeritus, EPFL (2017), University of Geneva (2017), University of Lausanne (2018) HONORS AND AWARDS (SELECTED): President, Swiss Society for Neuroscience (1997–1999) President, Federation of European Neuroscience Societies (FESN) (2002–2004) President, International Brain Research Organization (IBRO) (2014–2019) Member: Board of Trustees, Human Frontier Science Program (2003–2018) Vice Chairman, European Dana Alliance for the Brain (EDAB) (2002–) IPSEN Foundation Prize, Co-recipient with David Attwell and Marcus Raichle (2016) Honorary member of the Chinese Association for Physiological Sciences (2014) Camillo Golgi Medal Award, Golgi Foundation (2011) Goethe Award for Psychoanalytic Scholarship, Canadian Psychological Association (2009) International Chair Professor, Collège de France (2007–2008) Emil Kraepelin Guest Professorship, Max Planck Institute für Psychiatrie (2002) Member of the Swiss Academy of Medical Sciences, ad personam (2001) Member of Academia Europaea (2001) Pierre Magistretti has made important contributions to the study of brain energy metabolism and has pioneered the field of glia biology.
    [Show full text]
  • Floyd E. Bloom 1 Joaquín Fuster 58 Michael S
    The History of Neuroscience in Autobiography VOLUME 7 This page intentionally left blank The History of Neuroscience in Autobiography VOLUME 7 Edited by Larry R. Squire 1 1 Oxford University Press, Inc., publishes works that further Oxford University’s objective of excellence in research, scholarship, and education. Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi New Delhi Shanghai Taipei Toronto With offi ces in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam Copyright © 2012 by Society for Neuroscience Published by Oxford University Press, Inc. 198 Madison Avenue, New York, New York 10016 www.oup.com Oxford is a registered trademark of Oxford University Press All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press. ____________________________________________ Library of Congress Control Number: 96070950 ISBN-13: 978–0–19–539613–3 ____________________________________________ 1 3 5 7 9 8 6 4 2 Printed in the United States of America on acid-free paper Contents Previous Contributors vii Preface to Volume 1 ix Preface to Volume 7 xi Floyd E. Bloom 1 Joaquín Fuster 58 Michael S. Gazzaniga 98 Bertil Hille 140 Ivan Izquierdo 188 Edward Jones 232 Krešimir Krnjevic´ 278 Nicole M. Le Douarin 334 Terje L ømo 382 Michael M. Merzenich 438 John Wilson Moore 476 Robert Y. Moore 530 Michael I.
    [Show full text]
  • Jacques GLOWINSKI, Membre De L’Institut (Académie Des Sciences), Professeur
    Neuropharmacologie M. Jacques GLOWINSKI, membre de l’Institut (Académie des Sciences), professeur Le cours de cette année n’a pas eu lieu. Séminaires-Symposium En l’honneur de Anne-Marie THIERRY : Dopamine, Ganglions de la Base, Cortex Préfrontal : rétrospective et perspectives Modérateur : Jacques GLOWINSKI (Collège de France) Anne-Marie THIERRY (INSERM U.114, Collège de France) Dopamine, ganglions de la base et cortex préfrontal : chroniques internes. Jean-Michel DENIAU (INSERM U.114, Collège de France) Systèmes des ganglions de la base et traitement de l’information : évolution des concepts. Modérateur : Marie-Jo BESSON (Univ. P. & M. Curie, CNRS, Paris) Bruno DUBOIS (INSERM EPI007, Hôp. Salpêtrière, Paris) Aspects pathophysiologiques du cortex préfrontal et des circuits limbiques des ganglions de la base. Marie-Françoise CHESSELET (Dept Neurology, UCLA, Los Angeles, USA) Ganglions de la base et mouvements anormaux. Étienne HIRSCH (INSERM U.289, Hôp. Salpêtrière, Paris) Modifications métaboliques dans les pathologies des ganglions de la base. Stéphane CHARPIER (INSERM U.114, Collège de France) Striatum et traitement de l’information corticale. Marie-Lou KEMEL (INSERM U.114, Collège de France) Neuropeptides et « balance dopamine-acétylcholine » dans le striatum. 398 JACQUES GLOWINSKI Laurent VENANCE (INSERM U.114, Collège de France) Synapses électriques et interactions synaptiques locales dans le striatum. Modérateur : André NIEOULLON (CNRS, Marseille) Pierre POLLAK (Service de neurologie, Grenoble) Stimulation haute fréquence du noyau sous-thalamique : aspects cliniques. Guy CHOUVET (INSERM U.512, Lyon) Activité unitaire des neurones du noyau sous-thalamique chez le rat vigile. Marc SAVASTA (INSERM U.318, Grenoble) Mécanismes neurochimiques induits par la stimulation haute fréquence du noyau sous-thalamique : rôle possible du GABA dans son efficacité thérapeutique.
    [Show full text]
  • The Story of Julius Axelrod (1912-2004): a Testament to Commitment
    Review Article American Journal of Pharmacology Published: 15 Dec, 2019 The Story of Julius Axelrod (1912-2004): A Testament to Commitment Ronald PR* Department of Pharmacology and Toxicology, University at Buffalo, USA Abstract The key research of Julius Axelrod focused on the release, reuptake and storage of the neurotransmitters norepinephrine and epinephrine. These discoveries provided a new model for understanding the metabolism and regulation of neurotransmitters. In elucidating how neurotransmitters transmit their specific messages, Axelrod not only revolutionized research in catecholamine metabolism, but ultimately fostered the development of therapies for mental illness and pain relief. In 1970 Julius Axelrod was awarded the Nobel Prize in Physiology or Medicine for discoveries related to the mechanisms involved in the storage, release, and inactivation of neurotransmitters. Introduction Early years and education By possessing the best attributes in the broad area of science, Julius Axelrod was a compelling figure in biomedical research (Figure 1). As a former laboratory technician who became a pioneer in neurobiological research, his determination stands out as an example of anyone who is committed to realizing his/her ambitions. Raised by parents who were Jewish immigrants from Poland, his father was a basket maker who sold his wares from a horse-drawn wagon on the streets of lower Manhattan [1,2]. Despite his modest background, young Julius became interested in science, particularly in medicine, at an early age. However, these early years were met with a number of impediments and frustrations. He enrolled in New York University (NYU) in 1929; but had to transfer to the tuition- free College of the City of New York after one year, when he could no longer pay his tuition.
    [Show full text]
  • The Basal Ganglia Viii
    THE BASAL GANGLIA VIII ADVANCES IN BEHAVIORAL BIOLOGY Editorial Board Jan Bures Institute of Physiology, Prague, Czech Republic Irwin Kopin National Institute of Mental Health, Bethesda, Maryland Bruce McEwen Rockefeller University, New York, New York Karl Pribram Radford University, Radford, Virginia Jay Rosenblatt Rutgers University, Newark, New Jersey Lawrence Weiskranz University of Oxford, Oxford, England Recent Volumes in This Series Volume 39 THE BASAL GANGLIA III Edited by Giorgio Bernardi, Malcolm B. Carpenter, Gaetano Di Chiara, Micaela Morelli, and Paolo Stanzione Volume 40 TREATMENT OF DEMENTIAS: A New Generation of Progress Edited by Edwin M. Meyer, James W. Simpkins, Jyunji Yamamoto, and Fulton T. Crews Volume 41 THE BASAL GANGLIA IV: New Ideas and Data on Structure and Function Edited by Gérard Percheron, John S. McKenzie, and Jean Féger Volume 42 CALLOSAL AGENESIS: A Natural Split Brain? Edited by Maryse Lassonde and Malcolm A. Jeeves Volume 43 NEUROTRANSMITTERS IN THE HUMAN BRAIN Edited by David J. Tracey, George Paxinos, and Jonathan Stone Volume 44 ALZHEIMER’S AND PARKINSON’S DISEASES: Recent Developments Edited by Israel Hanin, Mitsuo Yoshia, and Abraham Fisher Volume 45 EPILEPSY AND THE CORPUS CALLOSUM 2 Edited by Alexander G. Reeves and David W. Roberts Volume 46 BIOLOGY AND PHYSIOLOGY OF THE BLOOD-BRAIN BARRIER: Transport, Cellular Interactions, and Brain Pathologies Edited by Pierre-Olivier Couraud and Daniel Scherman Volume 47 THE BASAL GANGLIA V Edited by Chihoto Ohye, Minoru Kimura, and John S. McKenzie Volume 48 KINDLING 5 Edited by Michael E. Corcoran and Solomon Moshé Volume 49 PROGRESS IN ALZHEIMER’S AND PARKINSON’S DISEASES Edited by Abraham Fisher, Israel Hanin, and Mitsuo Yoshida Volume 50 NEUROPSYCHOLOGY OF CHILDHOOD EPILEPSY Edited by Isabelle Jambaqué, Maryse Lassonde, and Olivier Dulac Volume 51 MAPPING THE PROGRESS OF ALZHEIMER’S AND PARKINSON’S DISEASE Edited by Yoshikuni Mizuno, Abraham Fisher, and Israel Hanin Volume 52 THE BASAL GANGLIA VII Edited by Louise F.B.
    [Show full text]
  • Julius Axelrod 50
    EDITORIAL ADVISORY COMMITTEE Albert J. Aguayo Bernice Grafstein Theodore Melnechuk Dale Purves Gordon M. Shepherd Larry W. Swanson (Chairperson) The History of Neuroscience in Autobiography VOLUME 1 Edited by Larry R. Squire SOCIETY FOR NEUROSCIENCE 1996 Washington, D.C. Society for Neuroscience 1121 14th Street, NW., Suite 1010 Washington, D.C. 20005 © 1996 by the Society for Neuroscience. All rights reserved. Printed in the United States of America. Library of Congress Catalog Card Number 96-70950 ISBN 0-916110-51-6 Contents Denise Albe-Fessard 2 Julius Axelrod 50 Peter O. Bishop 80 Theodore H. Bullock 110 Irving T. Diamond 158 Robert Galambos 178 Viktor Hamburger 222 Sir Alan L. Hodgkin 252 David H. Hubel 294 Herbert H. Jasper 318 Sir Bernard Katz 348 Seymour S. Kety 382 Benjamin Libet 414 Louis Sokoloff 454 James M. Sprague 498 Curt von Euler 528 John Z. Young 554 Julius Axelrod BORN: New York, New York May 30, 1912 EDUCATION: College of the City of New York, B.S., 1933 New York University, M.A., 1941 George Washington University, Ph.D., 1955 APPOINTMENTS" Goldwater Memorial Hospital, Third New York University Research Division (1946) National Heart Institute (1949) National Institute of Mental Health; Chief, Section on Pharmacology (1955) National Institute of Mental Health Guest Researcher (1984) Scientist Emeritus of the National Institutes of Health (1996) HONORS AND AWARDS (SELECTED): Nobel Prize for Physiology or Medicine (1970) American Academy of Arts and Sciences (1971) National Academy of Sciences USA (1971) Foreign Member of the Royal Society of London (1979) Leibniz Medal, Academy of Sciences, East Germany (1984) Mahoney Award "Decade of the Brain" (1991) Ralph W.
    [Show full text]
  • The Basal Ganglia Viii
    THE BASAL GANGLIA VIII ADVANCES IN BEHAVIORAL BIOLOGY Editorial Board Jan Bures Institute of Physiology, Prague, Czech Republic Irwin Kopin National Institute of Mental Health, Bethesda, Maryland Bruce McEwen Rockefeller University, New York, New York Karl Pribram Radford University, Radford, Virginia Jay Rosenblatt Rutgers University, Newark, New Jersey Lawrence Weiskranz University of Oxford, Oxford, England Recent Volumes in This Series Volume 39 THE BASAL GANGLIA III Edited by Giorgio Bernardi, Malcolm B. Carpenter, Gaetano Di Chiara, Micaela Morelli, and Paolo Stanzione Volume 40 TREATMENT OF DEMENTIAS: A New Generation of Progress Edited by Edwin M. Meyer, James W. Simpkins, Jyunji Yamamoto, and Fulton T. Crews Volume 41 THE BASAL GANGLIA IV: New Ideas and Data on Structure and Function Edited by Gérard Percheron, John S. McKenzie, and Jean Féger Volume 42 CALLOSAL AGENESIS: A Natural Split Brain? Edited by Maryse Lassonde and Malcolm A. Jeeves Volume 43 NEUROTRANSMITTERS IN THE HUMAN BRAIN Edited by David J. Tracey, George Paxinos, and Jonathan Stone Volume 44 ALZHEIMER’S AND PARKINSON’S DISEASES: Recent Developments Edited by Israel Hanin, Mitsuo Yoshia, and Abraham Fisher Volume 45 EPILEPSY AND THE CORPUS CALLOSUM 2 Edited by Alexander G. Reeves and David W. Roberts Volume 46 BIOLOGY AND PHYSIOLOGY OF THE BLOOD-BRAIN BARRIER: Transport, Cellular Interactions, and Brain Pathologies Edited by Pierre-Olivier Couraud and Daniel Scherman Volume 47 THE BASAL GANGLIA V Edited by Chihoto Ohye, Minoru Kimura, and John S. McKenzie Volume 48 KINDLING 5 Edited by Michael E. Corcoran and Solomon Moshé Volume 49 PROGRESS IN ALZHEIMER’S AND PARKINSON’S DISEASES Edited by Abraham Fisher, Israel Hanin, and Mitsuo Yoshida Volume 50 NEUROPSYCHOLOGY OF CHILDHOOD EPILEPSY Edited by Isabelle Jambaqué, Maryse Lassonde, and Olivier Dulac Volume 51 MAPPING THE PROGRESS OF ALZHEIMER’S AND PARKINSON’S DISEASE Edited by Yoshikuni Mizuno, Abraham Fisher, and Israel Hanin Volume 52 THE BASAL GANGLIA VII Edited by Louise F.B.
    [Show full text]
  • Solomon H. Snyder
    Solomon H. Snyder BORN: Washington, D.C. December 26, 1938 EDUCATION: Georgetown College, Washington, D.C. (1955–1958) Georgetown Medical School, Washington, D.C. M.D. Cum Laude (1962) APPOINTMENTS: Research Associate, NIH, (1963–1965) Resident, Psychiatry, Johns Hopkins (1965–1968) Assistant (1966–1968), Associate (1968–1970), Full (1970– ) Professor, Johns Hopkins, Pharmacology and Psychiatry Distinguished Service Professor of Neuroscience Pharmacology and Psychiatry, Johns Hopkins (1980– ) Director, Department of Neuroscience, Johns Hopkins (1980–2006) HONORS AND AWARDS (SELECTED): Honorary Doctorates: Northwestern University (1981) Georgetown University (1986) Ben Gurion University, Israel (1990) Albany Medical College (1998) Technion University, Israel (2002) Mount Sinai Medical School (2004) University of Maryland (2006) Awards: Albert Lasker Award (1978) Wolf Prize (1983) Bower Award (1992) National Medal of Science (2005) Albany Prize in Medicine (2007) Honorifi c Societies: American Academy of Arts and Sciences (1979) National Academy of Sciences USA (1980) Institute of Medicine (1988) American Philosophical Society (1992) Solomon Snyder identifi ed receptors for opiates and neurotransmitters and elucidated mechanisms of drug action. He characterized messenger systems including IP3 receptors and inositol pyrophosphates. He identifi ed novel neurotransmitters including nitric oxide, carbon monoxide and D-serine. Solomon H. Snyder ike most other people, I am the product of my parents. Hence, a brief review of their lives may provide insight into my own. Similarly, the Llives of my siblings may be informative. My dad was born in 1911 in Baltimore, the fi fth of seven children. His father moved to Washington when he was 2 years old to open a small grocery store a block away from the butcher shop operated by Al Jolson’s father.
    [Show full text]